PDCD1 and acute myeloid leukemia: The combination therapy group included the full spectrum of cancers treated with PD-1/PD-L1 agents, in addition to malignancies such as pleural mesothelioma, acute myeloid leukaemia (AML), chronic myeloid leukaemia (CML), Hodgkin lymphoma, papillary thyroid carcinoma, and cutaneous squamous cell carcinoma (cSCC) (Table 3).